S'abonner

Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsets - 06/10/15

Doi : 10.1016/j.jaci.2015.05.049 
Tali Czarnowicki, MD, MSc a, ∗, Hitokazu Esaki, MD a, b, ∗, Juana Gonzalez, PhD c, Dana Malajian, BA a, d, Avner Shemer, MD f, Shinji Noda, MD a, Sreya Talasila, MD e, Adam Berry, MS e, Jayla Gray, BS e, Lauren Becker, MD e, Yeriel Estrada, BS b, Hui Xu, MSc b, Xiuzhong Zheng, MSc a, Mayte Suárez-Fariñas, PhD b, g, h, James G. Krueger, MD, PhD a, Amy S. Paller, MD e, ‡, Emma Guttman-Yassky, MD, PhD a, b, ⁎, ‡
a Laboratory for Investigative Dermatology, Rockefeller University, New York, NY 
c Translational Technology Core Laboratory, Rockefeller University, New York, NY 
b Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 
g Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 
h Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 
d Columbia University College of Physicians and Surgeons, New York, NY 
e Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Ill 
f Department of Dermatology, Tel-Hashomer Hospital, Tel Aviv, Israel 

∗Corresponding author: Emma Guttman-Yassky, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai Medical Center, 5 E 98th St, New York, NY 10029.

Abstract

Background

Identifying differences and similarities between cutaneous lymphocyte antigen (CLA)+ polarized T-cell subsets in children versus adults with atopic dermatitis (AD) is critical for directing new treatments toward children.

Objective

We sought to compare activation markers and frequencies of skin-homing (CLA+) versus systemic (CLA−) “polar” CD4 and CD8 T-cell subsets in patients with early pediatric AD, adults with AD, and control subjects.

Methods

Flow cytometry was used to measure CD69/inducible costimulator/HLA-DR frequency in memory cell subsets, as well as IFN-γ, IL-13, IL-9, IL-17, and IL-22 cytokines, defining TH1/cytotoxic T (TC) 1, TH2/TC2, TH9/TC9, TH17/TC17, and TH22/TC22 populations in CD4 and CD8 cells, respectively. We compared peripheral blood from 19 children less than 5 years old and 42 adults with well-characterized moderate-to-severe AD, as well as age-matched control subjects (17 children and 25 adults).

Results

Selective inducible costimulator activation (P < .001) was seen in children. CLA+ TH2 T cells were markedly expanded in both children and adults with AD compared with those in control subjects, but decreases in CLA+ TH1 T-cell numbers were greater in children with AD (17% vs 7.4%, P = .007). Unlike in adults, no imbalances were detected in CLA− T cells from pediatric patients with AD nor were there altered frequencies of TH22 T cells within the CLA+ or CLA− compartments. Adults with AD had increased frequencies of IL-22–producing CD4 and CD8 T cells within the skin-homing population, compared with controls (9.5% vs 4.5% and 8.6% vs 2.4%, respectively; P < .001), as well as increased HLA-DR activation (P < .01).

Conclusions

These data suggest that TH2 activation within skin-homing T cells might drive AD in children and that reduced counterregulation by TH1 T cells might contribute to excess TH2 activation. TH22 “spreading” of AD is not seen in young children and might be influenced by immune development, disease chronicity, or recurrent skin infections.

Le texte complet de cet article est disponible en PDF.

Key words : Atopic dermatitis, T cell, cutaneous lymphocyte antigen, IL-13, IL-22, IFN-γ, inducible costimulator, CD69, HLA-DR

Abbreviations used : AD, CLA, ICOS, PE, PMA, TC, TCM, TEM


Plan


 Supported by a research grant from the LEO Foundation (research grant no. 0266-2572, GCO no. 13-1310 to E.-G.-Y. and A.S.P.). T.C. was cosponsored by the Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust. J.G. was supported in part by grant no. UL1TR0000 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. D.M. received funding from the American Dermatological Association Medical Student Fellowship. J.G.K. was supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Blood acquisition was supported by the Northwestern University Skin Disease Research Center (NIAMS P30AR057216).
 Disclosure of potential conflict of interest: J. G. Krueger reports that money was paid to his institution by and/or he has received personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, BiogenIdec, Delenex, AbbVie, Sanofi, Baxter, Parexel, Xenoport, and Kineta. A. S. Paller has received research support from the LEO Foundation; has received consultancy fees from Abbvie, Anacor, Celsus, Chugai Pharma, Galderma, GSK-Stiefel, Novartis, and Promius Pharma; and is an investigator for Abbvie. E. Guttman-Yassky is a board member for Sanofi Aventis, Regeneron, Stiefel/GSK, Medimmune, Celgene, Anacor, and Leo Pharma; has received consultancy fees from Regeneron, Sanofi Aventis, Medimmune, Celgene, Steifel/GSK, Celsus, BMS, Amgen, and Drais; and has received research support from Regeneron, Celgene, BMS, and Janssen. The rest of the authors declare that they have no relevant conflicts of interest.


© 2015  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 136 - N° 4

P. 941 - octobre 2015 Retour au numéro
Article précédent Article précédent
  • Prediction and prevention of allergic rhinitis: A birth cohort study of 20 years
  • Linus B. Grabenhenrich, Thomas Keil, Andreas Reich, Hannah Gough, John Beschorner, Ute Hoffmann, Carl-Peter Bauer, Johannes Forster, Antje Schuster, Dirk Schramm, Oliver Nitsche, Fred Zepp, Young-Ae Lee, Renate Bergmann, Karl Bergmann, Ulrich Wahn, Susanne Lau
| Article suivant Article suivant
  • Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials
  • Carlos A. Cuello-Garcia, Jan L. Bro?ek, Alessandro Fiocchi, Ruby Pawankar, Juan José Yepes-Nuñez, Luigi Terracciano, Shreyas Gandhi, Arnav Agarwal, Yuan Zhang, Holger J. Schünemann

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.